News

Virginia Catalyst Announces Grant Round 15 Awarded Projects

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $2.2 million in grants to four life and bioscience projects in the Commonwealth of Virginia. These four collaborative projects, involving Virginia research universities and industry partners, were awarded through Virginia Catalyst Grant Round 15 to address major unmet healthcare needs and drive job creation and capital formation in Virginia.

Through this 15th round of funding, Virginia Catalyst has awarded 61 grants totaling $29.7 million, resulting in over $47 million in matching funds and an additional $821 million in follow-on funding to date.

Grant Round 15 awarded projects:

Project: Transforming Asthma Treatment with a New Generation A2B Adenosine Receptor Antagonist

  • Company: Adovate, LLC  (Charlottesville, VA)
  • University collaborators: University of Virginia and Virginia Tech
  • Funding amount: $800,000

Project: Optimization of a Wearable Enteral Feeding System for Commercialization

  • Company: Luminoah, Inc. (Charlottesville, VA)
  • University collaborators: University of Virginia and Virginia Commonwealth University
  • Funding amount: $463,000

Project: Pre-clinical Evaluation of an Implant Device for the Regeneration of Severe Osteochondral Defects, Utilizing a Proven Novel Material and 3D Printing

  • Company: Nanochon, Inc. (Washington, DC)
  • University collaborators: Virginia Tech and University of Virginia
  • Funding amount: $445,000

Project: Blocking the S1P Pathway for Chronic Kidney Disease Therapeutics

  • Company: S1P Therapeutics, Inc. (Blacksburg, VA)
  • University collaborators: Virginia Tech and University of Virginia
  • Funding amount: $500,000

Recent News

11/11/2025

Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the target loading concentrations for its two topical rapamycin delivery technologies have been successfully achieved. Specifically, a rapamycin loading concentration of 4% w/w has been achieved for Quoin’s proprietary topical

11/07/2025

Dan Myers Named Director of Virginia SBDC, Innovation Commercialization Assistance Program to Accelerate Tech-Driven Growth in the Commonwealth

The Virginia Small Business Development Center (SBDC) is pleased to announce that Dan Myers has been named the new Director for the Virginia SBDC – Innovation Commercialization Assistance Program (ICAP). Dan, a seasoned innovation strategist, will lead the Virginia SBDC – ICAP program that is designed to help Virginia small businesses turn ideas into commercial

11/06/2025

Luna Labs’ MedSim Product Lines Acquired by Integrated Medcraft

Integrated MedCraft LLC today announced it has acquired the TrueClot and Dislotech product lines from Luna Labs. This announcement is more than a successful transaction. It is an example of innovation being accelerated with the right strategic partner. We built Luna Labs with a clear mission to incubate, accelerate, and grow technologies to the point